Ariela Katz


MDM2 Inhibitor May Improve Response in Acute Myeloid Leukemia

October 20, 2018

Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, is being tested in combination with cytarabine in the international phase III MIRROS clinical trial (NCT02545283) to see if omprove the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML).

Investigating the Potency of CAR T-Cell Therapy in Relapsed/Refractory MCL

October 19, 2018

The value of axicabtagene ciloleucel (axi-cel; Yescarta), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in treating R/R MCL will be tested in the multi­center phase II ZUMA-2 clinical trial (NCT02601313).

FDA Grants Rucaparib Breakthrough Designation for mCRPC

October 02, 2018

The FDA has granted the PARP inhibitor rucaparib (Rubraca) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Glutaminase Inhibitor That Starves Tumor Cells May Improve Survival in Metastatic RCC

September 11, 2018

A novel glutaminase inhibitor, CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma (RCC).

Novel RET Inhibitor Tested in Patients With NSCLC, MTC

September 11, 2018

The phase I open-label LIBRETTO-001 clinical trial is currently testing LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other tumors with increased RET activity.

Potent Hypomethylating Agent Is Tested in 2 Hematologic Malignancy Trials

July 20, 2018

Two randomized phase III clinical trials are designed to determine whether guadecitabine (SGI-110), a potent second-generation hypomethylating agent, could answer unmet medical needs for patients with certain types of blood cancer.

Promising Umbralisib Combinations Tested in Non-Hodgkin Lymphoma Subtypes

June 26, 2018

The phase IIb UNITY-NHL clinical trial (NCT02793583) aims to determine whether the novel drug umbralisib (TGR-1202) could be used as monotherapy or in combination with other drugs to treat patients with relapsed/refractory non-Hodgkin lymphoma (NHL).